We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SOPHiA GENETICS Acquires Interactive Biosoftware to Drive Growth
Product News

SOPHiA GENETICS Acquires Interactive Biosoftware to Drive Growth

SOPHiA GENETICS Acquires Interactive Biosoftware to Drive Growth
Product News

SOPHiA GENETICS Acquires Interactive Biosoftware to Drive Growth


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SOPHiA GENETICS Acquires Interactive Biosoftware to Drive Growth"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SOPHiA GENETICS, global leader in Data-Driven Medicine, announced at the European Human Genetics Conference (ESHG 2018) that it has completed the acquisition of French-based tech company Interactive Biosoftware (IBS), the creators of Alamut®, the most used decision support software for clinical genomic data interpretation.

Alamut® is currently deployed in over 450 hospitals and is highly complementary to SOPHiA GENETICS' offering. This is an important milestone that will further accelerate the adoption of Data-Driven Medicine around the world.

The acquisition reinforces SOPHiA GENETICS' commitment to continuously support hospitals and patients with powerful technologies. Interactive Biosoftware's expertise and teams will join SOPHiA GENETICS' workforce. A seamless onboarding will ensure Alamut® users' experience.

"Interactive Biosoftware has been highly successful in providing powerful technology for experts with complex genomic interpretation needs. It is great to join SOPHiA GENETICS' unique approach and position to accelerate Data-Driven Medicine's adoption." - André Blavier CEO & Founder at Interactive Biosoftware.

"We are very excited about the acquisition of Interactive Biosoftware. Both SOPHiA AI and Alamut® are technologies trusted by the healthcare community and focus on patient-centric innovation. The addition of Alamut® marks a big step in our aim to help clinicians better diagnose patients equally. With a community of now over 900 teaching hospitals using our technologies we are in a unique position to connect clinicians and enable them to share knowledge." - Jurgi Camblong, CEO & Co-founder at SOPHiA GENETICS.
Advertisement